Drugs / EO2002
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05636579 | Nov 2022 → Dec 2025 overdue | Fuchs' endothelial dystrophy, bullous keratopathy | Asociación para Evitar la Ceguera en México | Recruiting | No outcome recorded |
| Phase 1 | NCT05587205 | Aug 2022 → Oct 2026 expected | cataract, corneal disorder | Asociación para Evitar la Ceguera en México | Recruiting | No outcome recorded |
| Phase 1 | NCT04894110 | Jun 2021 → Oct 2024 | Fuchs' endothelial dystrophy, bullous keratopathy | Emmecell | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07729137 | Oct 2026 → Aug 2027 expected | Fuchs atrophia gyrata chorioideae et retinae, Fuchs' endothelial dystrophy, bullous keratopathy | Emmecell | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EO2002 | “This study is designed to evaluate the safety and efficacy of EO2002, an investigational magnetic human corneal endothelial cell (mHCEC) therapy, in adults with corneal edema...” NCT07729137 ↗ |
| Known as | Magnetic Human Corneal Endothelial Cells | “Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery” NCT05587205 ↗ |
| Modality | Cell therapy | “inject cultured human corneal endothelial cells (HCECs) into the anterior chamber of the eye” NCT04894110 ↗ |
| Route | Other | “inject cultured human corneal endothelial cells (HCECs) into the anterior chamber of the eye” NCT04894110 ↗ |